Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT01082939 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Alemtuzumab
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]